PTD-DBM is a cell-permeable peptide that activates the Wnt/β-catenin signaling pathway, a key regulator of hair follicle development and cycling. In preclinical studies, topical application of PTD-DBM promoted new hair growth in mice by stimulating dermal papilla cells. It represents a novel peptide-based approach to androgenetic alopecia that targets the molecular biology of hair follicle stem cells rather than hormonal pathways like finasteride.
Category: Hair Growth. Evidence rating: D (animal/preclinical only).
Clinical status: Preclinical only. No human clinical trials initiated as of 2025.
PTD-DBM contains a protein transduction domain fused to a Dishevelled-binding motif that stabilizes β-catenin by inhibiting its phosphorylation and degradation. Stabilized β-catenin translocates to the nucleus and activates Wnt target genes that promote hair follicle neogenesis and anagen (growth…
Safety considerations: No human safety data available; Topical application in mice showed no reported adverse effects in published studies; Wnt/β-catenin pathway activation carries theoretical oncogenicity risk, as this pathway is implicated in multiple cancers.
Reviewed by the PeptideAtlas Editorial Team. Last reviewed: 2026-08-12.
Unknown. All published data is from mouse models. No human clinical trials have been conducted. The Wnt/β-catenin mechanism is scientifically plausible for hair growth, but translation from mice to humans is uncertain.
There is no human safety data. The Wnt/β-catenin pathway is a known oncogenic pathway, so chronic activation raises theoretical cancer concerns, particularly for skin cancers.
PTD-DBM targets an entirely different pathway (Wnt/β-catenin) than minoxidil (vasodilation/potassium channel) or finasteride (5-alpha reductase inhibition). It is far less studied than either approved treatment.